School of Biological Sciences, 60 Nanyang Drive, Nanyang Technological University, Singapore 637551, Singapore.
Department of Biophysics, Bose Institute, Unified Academic Campus, Saltlake, Sector V, EN 80, Kolkata 700091, India.
Int J Mol Sci. 2022 Apr 20;23(9):4558. doi: 10.3390/ijms23094558.
Global rise of infections and deaths caused by drug-resistant bacterial pathogens are among the unmet medical needs. In an age of drying pipeline of novel antibiotics to treat bacterial infections, antimicrobial peptides (AMPs) are proven to be valid therapeutics modalities. Direct in vivo applications of many AMPs could be challenging; however, works are demonstrating encouraging results for some of them. In this review article, we discussed 3-D structures of potent AMPs e.g., polymyxin, thanatin, MSI, protegrin, OMPTA in complex with bacterial targets and their mode of actions. Studies on human peptide LL37 and de novo-designed peptides are also discussed. We have focused on AMPs which are effective against drug-resistant Gram-negative bacteria. Since treatment options for the infections caused by super bugs of Gram-negative bacteria are now extremely limited. We also summarize some of the pertinent challenges in the field of clinical trials of AMPs.
全球范围内，耐药细菌病原体导致的感染和死亡病例不断增加，这是未满足的医疗需求之一。在新型抗生素治疗细菌感染的研发管道日渐枯竭的时代，抗菌肽（AMPs）已被证实是一种有效的治疗方法。然而，许多 AMPs 的直接体内应用具有挑战性；但是，针对其中一些 AMPs 的研究已经取得了令人鼓舞的结果。在这篇综述文章中，我们讨论了一些强效 AMPs 的 3-D 结构，例如多粘菌素、thanatin、MSI、防御素、OMPTA 与细菌靶标的复合物及其作用模式。同时还讨论了人类肽 LL37 和从头设计的肽的研究。我们专注于对耐药革兰氏阴性菌有效的 AMPs。由于目前针对革兰氏阴性菌超级细菌感染的治疗选择极为有限。我们还总结了抗菌肽临床试验领域的一些相关挑战。
